Hypofractionated versus conventional radiotherapy for head-and-neck cancer: A systematic review and meta-analysis

The objective of the study was to compare the efficacy and toxicity of hypofractionated radiotherapy versus conventional fractionated radiotherapy in head-and-neck cancer patients using meta-analysis. PubMed, Embase, Cochrane CENTRAL, and ClnicalTrials.gov were searched to identify the trials comparing conventionally fractionated radiotherapy versus hypofractionated radiotherapy in head-and-neck cancer patients. Compete response (CR) was the primary endpoint, and partial response (PR), overall survival (OS), disease-free survival (DFS), progressive disease (PD), stable disease (SD), local regional recurrence (LRR), acute skin toxicity, and mucositis were the secondary endpoints. This study is registered in PROSPERO (CRD42024513677) and includes the PRISMA checklist also. This meta-analysis included six controlled clinical trials with 310 head-and-neck cancer patients. No significant differences in CR were revealed by this meta-analysis performed by us (odds ratio [OR] =0.94, 95% confidence interval [CI] =0.51–1.71, P = 0.83), PR (OR = 0.97, 95% CI = 0.48–1.97, P = 0.93), LRR (OR = 1.45, 95% CI = 0.71–2.95, P = 0.31), DFS (OR = 0.87, 95% CI = 0.20–3.83, P = 0.86), OS (OR = 0.83, 95% CI = 0.16–4.40, P = 0.83), SD (OR = 1.82, 95% CI = 0.45–7.36, P = 0.40), PD (OR = 0.79, 95% CI = 0.18–3.46, P = 0.75), Acute skin toxicity (OR = 1.75, 95% CI = 0.61–5.05, P = 0.30), and mucositis (OR = 2.9, 95% CI = 0.35–24.25, P = 0.33 between the two groups. Our study’s results indicate that the efficacy and safety of hypofractionated radiotherapy do not notably differ from those of conventional fractionated radiotherapy.

• Publication year

  2025

• Venue

  Annals of Oncology Research and Therapy

• Publication date

  2025-01-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.4103/aort.aort_37_24
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors

  2022cited by this paper
• TREATMENT OUTCOME AND TOXICITY OF HYPOFRACTIONATED RADIOTHERAPY WITH CONCOMITANT CHEMOTHERAPY VERSUS CONVENTIONAL FRACTIONATED CONCOMITANT CHEMORADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CARCINOMA: A COMPARATIVE STUDY

  2022cited by this paper
• Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

  2021cited by this paper
• Hypofractionated radiotherapy versus conventional radiotherapy in early glottic cancer T1-2N0M0: A randomized study

  2021cited by this paper
• “Christie Regimen” palliative radiotherapy in advanced head-and-neck cancer: A single-center experience

  2021cited by this paper
• Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.

  2020cited by this paper
• Advanced head and neck cancer in older adults: Results of a short course accelerated radiotherapy trial.

  2020cited by this paper
• Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review

  2020cited by this paper
• Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement

  2020cited by this paper
• Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis

  2020cited by this paper
• Hypofractionated Versus Conventional Radiotherapy with Chemotherapy in Head and Neck Cancer: A Comparative Study

  2020cited by this paper
• Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes

  2019cited by this paper
• The role of hypofractionated radiotherapy in the management of head and neck cancer - a modelling approach.

  2019cited by this paper
• Effectiveness and toxicity of hypofractionated high‐dose intensity‐modulated radiotherapy versus 2‐ and 3‐dimensional radiotherapy in incurable head and neck cancer

  2016cited by this paper
• Hypofractionated versus conventional radiotherapy with or without chemotherapy in head and neck cancer: A comparative study

  2015cited by this paper
• Four Week Hypofractionated Accelerated Intensity Modulated Radiotherapy and Synchronous Carboplatin or Cetuximab in Biologically Staged Oropharyngeal Carcinoma

  2014cited by this paper
• Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients

  2014cited by this paper
• Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer

  2012cited by this paper
• Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.

  2011cited by this paper
• Evaluation of the Treatment Response after Hypofractionated Radiotherapy in Patients with Advanced Head and Neck Cancers

  2009cited by this paper
• Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Oral sequelae of head and neck radiotherapy.

  2003cited by this paper
• Estimates of cancer incidence and mortality in Europe in 1995.

  2002cited by this paper
• Impact of radiation therapy fraction size on local control of early glottic carcinoma.

  1997cited by this paper
• Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.

  1996cited by this paper

• No citing papers are available for this paper.